Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

NCT01622569 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
323
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Optinose US Inc.